Management of Venous Thromboembolism and Atrial Fibrillation in Patients with Cancer. The Role of Direct Oral Anticoagulants by Anninos, Hector & Manolis, Antonis S
5 
 
 
REVIEW 
  
Management of Venous Thromboembolism and Atrial 
Fibrillation in Patients with Cancer. The Role of Direct 
Oral Anticoagulants  
 
Hector Anninos, MD, Antonis S. Manolis, MD 
 
Athens University School of Medicine, Athens, Greece 
 
ABSTRACT 
 
Cancer is accompanied by an increase of both thrombotic 
and hemorrhagic complications. Thus, the management of 
venous thromboembolism (VTE) or atrial fibrillation (AF) 
presents certain difficulties in oncologic patients. So far, low 
molecular weight heparins (LMWHs) have been proved the most 
effective and safe agents for long-term use in the VTE setting. 
However, the novel oral anticoagulants (Direct Oral Anti-
Coagulants-DOACs), which are more friendly to use and begin 
to displace conventional anticoagulation in non-cancer patients, 
emerge as an attractive alternative. We present the latest data 
from randomized trials, meta-analyses of DOACs in oncologic 
populations and recent recommendation papers, as these agents 
claim their role in the management of cancer patients. Rhythmos 
2019;14(1):5-9. 
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Introduction 
 
Malignant diseases pose an increased thrombotic risk 
upon patients, reaching a prevalence of 5-10%, which 
corresponds to a four to seven-fold increase over cancer-
free individuals.1-3 Several factors contribute to this 
predisposition and a risk score has been developed to 
assess the thromboembolic risk of patients receiving 
chemotherapy and guide management (Table 1).4,5 
Moreover, the frequent interventions these patients 
undergo, the use of anti-cancer therapy with potential 
vascular toxicity and the concurrent bleeding risk due to 
the cancer itself or the drug-induced thrombocytopenia 
further complicates the issue. So far, antithrombotic 
therapy has been confined to parenteral heparin and low 
molecular weight heparins (LMWH), but the novel orally 
administered anticoagulants forcefully seek their place in 
this clinical scenario offering ease of use and potentially 
improved compliance. We herein briefly summarize the 
latest data on the use of direct oral anticoagulants 
(DOACs) regarding their efficacy and safety in patients 
with malignancies to determine their emerging role in the 
prevention and treatment of venous thromboembolism 
(VTE). 
 
Table 1. The Khorana score 4 
 
Patient Characteristic  Score 
Site of cancer 
 
 
   Very high risk (stomach, pancreas)  
 
2 
High risk (lung, lymphoma, gynecologic, 
genitourinary excluding prostate) 
1 
Platelet counts ≥ 350,000 per mm3 1 
Leukocyte counts > 11,000 per mm3 1 
Hemoglobin< 10 g/dL or use of ESAs 1 
BMI ≥ 35 kg/m2 1 
High risk: score ≥ 3 / Intermediate risk: score 1 – 2 / Low risk: 
score 0. BMI = body mass index, ESAs = erythropoiesis-
stimulating agents 
 
Definitions 
 
Active cancer is defined as: cancer diagnosed within 
the previous 6 months; recurrent, regionally advanced or 
metastatic cancer; cancer for which treatment had been 
administered within 6 months; or hematological cancer 
that is not in complete remission 6. 
 
Recent guidelines 
 
Several national and international societies have dealt 
with the issue of antithrombotic management in active 
cancer, as it came up shortly after the introduction of the 
novel oral agents in clinical practice. The European 
Society of Cardiology recommends the use of LMWH for 
the first 3-6 months after an acute thrombotic/ 
thromboembolic episode instead of vitamin K antagonists 
(VKA).7,8 The American College of Chest Physicians 
(ACCP) proposes the use of LMWH over VKA or any of 
the novel oral agents.9 The European Society of Medical 
Oncology (ESMO) recommends unfractionated heparin 
(UFH) or LMWH in the acute setting and LMWH in 
chronic basis.10 The American Society of Clinical 
Oncology (ASCO) prioritizes LMWH both for 
prophylaxis and long term treatment.11 The same 
suggestions are endorsed by the International Society on 
Thrombosis and Hemostasis (ISTH), International 
Initiative on Thrombosis and Cancer (ITAC-CME) and 
National Comprehensive Cancer Network (NCCN).12-14  
These statements do not provide robust 
recommendations on the use of novel oral anticoagulants 
as extensive evidence at the time of their completion was 
lacking. They are based on several trials comparing 
LMWH versus VKAs in patients with malignant disease,15-
18 the most emblematic among them being the CLOT trial, 
19 which showed that extended administration of daltaparin 
was more effective than VKA in reducing the risk of 
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recurrent thromboembolism in cancer patients, without 
affecting bleeding rates or mortality. 
 
Contemporary evidence 
 
Since the publication of the aforementioned guiding 
statements new data have been gathered that deserve 
discussion. Initially, subgroup analyses of patients with 
cancer from the population enrolled in the clinical trials of 
DOACs were performed and showed that all four drugs 
(dabigatran, rivaroxaban, apixaban, edoxaban) were 
comparably efficient and safe with warfarin in the 
subpopulation with active cancer.20-23  
At the same time, meta-analyses of these large trials, 
which included a small number of cancer patients, became 
available. Vedovati et al analyzed 6 trials (AMPLIFY 
2013, EINSTEIN-DVT 2010, EINSTEN-PE 2012, 
HOKUSAI VTE 2013, RECOVER I & II 2013) comparing 
all four DOACs with conventional anticoagulants. The 
number of patients with malignancies in the individual 
studies comprised 2.5%-9.4% of the total study population 
and in total they reached 1132 patients. DOACs were 
associated with a non-significant risk reduction for 
recurrent thromboembolic events and major bleeding 
when compared with VKA. 24  
Similar results were reported by Brunetti et al who 
performed a meta-analysis of 9 studies (AMPLIFY 2013, 
EINSTEIN-DVT 2010, EINSTEN-PE 2012, HOKUSAI 
VTE 2013, RECOVER I & II 2013, MAGELLAN 2011, 
ADOPT 2011, RE-MEDY 2103), with the 6 of them being 
common with the former meta-analysis, while this meta-
analysis included two additional studies which compared 
rivaroxaban and apixaban with LMWH for 
thromboprophylaxis (MAGELLAN 2011, ADOPT 2011). 
DOACs showed a non-significant reduction in 
thromboembolism and bleeding rates in comparison to 
LMWH followed by VKA. Interestingly, the reduction in 
hemorrhagic episodes was driven by the difference 
between DOACs and VKA. When compared to LMWH 
only, DOACs were associated with a significant rise in 
bleeding complications.25  
More recently, another meta-analysis was published, 
focusing on rivaroxaban. The authors used data from the 
subgroup analysis of the EINSTEIN-DVT and 
EINSTEIN-PE trials, along with another three relatively 
small retrospective studies comparing rivaroxaban to 
enoxaparin or warfarin in cancer patients. The analysis 
revealed a non-significant decrease in VTE recurrence and 
major bleeding in the rivaroxaban group. 26  
In 2018, two randomized clinical trials comparing 
DOACs with LMWH for the treatment of VTE in cancer 
patients were published. The Hokusai VTE Cancer trial 
was a non-inferiority trial which enrolled 1046 patients 
with active cancer or cancer diagnosed within the previous 
two years, excluding basal-cell or squamous-cell skin 
carcinomas, who had symptomatic or incidentally detected 
pulmonary embolism or deep vein thrombosis in the 
popliteal vein or above it. 27 They were randomly assigned 
in a 1:1 ratio to at least 5 days of any LMWH followed by 
edoxaban 60 mg daily versus dalteparin 200IU/kg daily for 
30 days followed by 150 IU/kg daily. Patients with reduced 
creatinine clearance (30-50 ml/min), low body weight 
(<60 kg) or on P-glycoprotein inhibitors, would receive 
edoxaban 30 mg daily. Treatment was continued for at 
least 6 months and up to 12 months, at the discretion of the 
attending physician. The primary end-point was a 
composite of recurrent venous thromboembolism or major 
bleeding. Recurrent thromboembolism, major bleeding 
and all-cause death were all included in the secondary end-
points. The primary outcome occurred in 12.8% of patients 
in the edoxaban arm vs 13.5% in the dalteparin arm 
(hazard ratio - HR, 0.97; p = 0.006 for non-inferiority; p = 
0.87 for superiority). Recurrent thromboembolism and 
total mortality did not differ. Major bleeding was 
significantly more common among patients treated with 
edoxaban (HR, 1.77; p = 0.04), a difference driven by 
upper gastrointestinal bleeding mainly in patients 
diagnosed with gastrointestinal malignancies. However, 
severe major bleeding events (hemodynamic instability, 
intracranial hemorrhage, fatal hemorrhage) were equally 
distributed between study groups. 27  
The SELECT-D trial allocated 406 patients with active 
cancer and symptomatic pulmonary embolism (PE), 
incidental PE, or symptomatic lower extremity proximal 
deep vein thrombosis (DVT) to dalteparin (200 IU/kg daily 
for one month followed by 150 IU/kg daily for 5 months) 
or rivaroxaban (15 mg bid for 3 weeks and then 20 mg per 
day for a total of 6 months) in a 1:1 fashion.28 The primary 
end point was the recurrent VTE during the 6 months of 
the trial. Safety end points included major bleeding and 
clinically relevant non-major bleeding. Rivaroxaban was 
associated with lower VTE recurrence than dalteparin 
(HR, 0.43), albeit with an increased occurrence of 
clinically relevant non-major bleeding (HR, 3.76). Major 
bleeding incidence did not differ between study arms. 
Most episodes were of gastrointestinal (GI) origin and 
esophageal or gastric cancer were more commonly 
involved. 28  
Al Yami et al performed a meta-analysis which 
included Hokusai VTE cancer study in its analysis, 
together with RE-COVER I, RE-COVER II, EINSTEIN-
DVT, EINSTEIN-PE, RE-MEDY,AMPLIFY, Hokusai-
VTE.29 The authors compared DOACs vs LMWH 
followed by VKA or LMWH (Hokusai VTE cancer) over 
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the efficacy outcome of VTE recurrence and safety 
outcome of major bleeding or clinically relevant non-
major bleeding. DOACs decreased VTE recurrence in 
patients with cancer compared with conventional 
anticoagulants by 36% (relative risk - RR = 0.64) without 
any significant influence on bleeding rates (RR = 1.00) 29. 
A latest meta-analysis of randomized trials, the 
majority of which were performed exclusively in patients 
with active cancer, including the two most recent 
SELECT-D and HOKUSAI VTE Cancer studies, showed 
that DOACs reduced VTE recurrence rate by 28% in 
comparison to LMWH (RR: 0.72) and by 54% in 
comparison to VKAs (RR: 0.46).30 Not surprisingly, 
LMWH was more effective than VKAs (RR: 0.64). There 
was a trend towards more major bleeding events when 
DOACs were used vs LMWH (RR: 1.14) and fewer events 
when DOACs or LMWH were used vs VKAs (RR, 0.85 
and RR, 0.75 respectively). The authors concluded that 
DOACs are probably the most effective while LMWHs are 
the safest agents. All-cause mortality did not differ 
between any of the three anticoagulant classes. 30 Similar 
results were obtained by the meta-analysis of Li et al. 31  
 
Guidelines update 
 
In view of the latest evidence, the oncology-related 
scientific societies incorporated the data on DOACs in the 
updated versions of the relevant guidelines. So far, the 
ISTH has published recommendations in 2018 where the 
use of DOACs is recommended for cancer patients with 
new VTE, low risk of bleeding and no interaction between 
the anticoagulant and their oncologic medication. 
Rivaroxaban and edoxaban are the preferred choices as 
these drugs have been tested in randomized trials. 6  
The Italian Society of Internal Medicine (SIMI) has 
recently published a comprehensive position paper which 
recognizes the emerging role of DOACs (presently 
rivaroxaban and edoxaban) in cancer patients with VTE 
and low risk for hemorrhage, but still lends its support to 
the well tested option of LMWH both in the acute phase 
and in the long-term management. 32  
Imberti et al, in an expert guidance article, recommend 
the use of DOACs, prioritizing edoxaban, in the 
management of VTE in patients with cancer and no 
contraindications. 33  
 
Atrial fibrillation 
 
In the clinical setting of atrial fibrillation (AF) the 
evidence regarding oncologic patients is still scarce and is 
derived mainly from analyses of patients with cancer 
included in the large randomized trial of DOACs in AF. In 
an analysis from the ARISTOTLE trial, the efficacy and 
safety of apixaban compared with warfarin as established 
in the original study were preserved among the patients 
with malignant diseases. Apixaban was associated with a 
better outcome in terms of the composite of stroke/ 
systemic embolism, myocardial infarction, and death in 
active cancer (HR 0.30) in comparison to patients without 
cancer (HR 0.86). This advantage was lost in remote 
cancer (HR 1.46). 34  
A total of 1153 patients from the ENGAGE AF-TIMI 
48 Trial who were diagnosed post-randomization with 
cancer or recurrence of remote malignancy were analyzed 
by Fanola et al. The efficacy of edoxaban versus warfarin 
was consistent regardless of the co-existence of cancer or 
not in terms of stroke/systemic embolism both in high and 
low dosing. 35  
Two more studies have addressed the use of DOACs 
in cancer patients with AF, without however performing 
any comparison with other anticoagulants. The first study 
which aimed to assess the thromboembolic and bleeding 
risk in this population, enrolled 1999 patients without 
cancer and 289 patients with cancer (active or remote) and 
non-valvular AF treated with any DOAC their physician 
would prefer. Thromboembolic events as well as major 
bleeding were more frequent in cancer patients (2.1% vs 
0.8% patient-year, HR 2.58 and 6.6% vs 3% patient-year, 
HR 2.02, respectively). Thromboembolic risk was highest 
among patients with active cancer, and the increased 
incidence of major bleeding in oncologic patients was 
attributed to gastrointestinal hemorrhage. 36  
The second study was conducted to assess the safety 
and efficacy of rivaroxaban in patients with active cancer 
and AF. A total of 163 patients were identified in the 
medical records. The estimated 1-year cumulative 
incidence of ischemic stroke was 1.4% and major bleeding 
was 1.2%. The authors concluded that the efficacy and 
safety of rivaroxaban in patients with active cancer and AF 
is comparable to that reported in the general population of 
the ROCKET-AF trial 37. 
 
Conclusion 
 
More data are obtained every day to help us decide 
whether and when to use the DOACs in patients with VTE 
or AF and active malignancies. In the AF setting the 
information in the literature is still limited. In the 
management of VTE, so far these drugs seem equally 
effective in this group of patients as in the general 
population, without severely compromising safety. A trend 
towards or a slight increase of bleeding complications in 
comparison to LMWH is the common finding of 
randomized trials and meta-analyses. Sobieraj et al. 
concluded in their meta-analysis that DOACs are probably 
the most effective and LMWH the safest choice.  
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Table 2. Ongoing clinical trials testing DOACs in oncologic patients with VTE 38 
 
Study 
 
ClinicalTrials. 
gov identifier 
DOAC Comparator 
The CAP Study: Apixaban as treatment of 
venous thrombosis in patients with cancer 
NCT02581176 Apixaban None 
ADAM-VTE: A phase III, randomized, open-
label study evaluating apixaban safety in subjects 
with cancer-related venous thrombo-embolism 
NCT02585713 Apixaban Dalteparin 
CARAVAGGIO: Apixaban for the treatment of 
venous thromboembolism in patients with cancer 
NCT03045406 Apixaban Dalteparin 
PRIORITY: randomized phase II study to 
compare the safety and efficacy of dalteparin 
versus rivaroxaban for cancer associated venous 
thromboembolism 
NCT03139487 Rivaroxaban Dalteparin 
CASTA-DIVA: Cancer-associated thrombosis, a 
pilot treatment study using rivaroxaban 
NCT02746185 Rivaroxaban Dalteparin 
CANVAS: DOACs versus LMWH ± warfarin 
for VTE in cancer  
NCT02744092 Rivaroxaban Apixaban Edoxaban 
Dabigatran 
Dalteparin, enoxaparin, 
fondaparinux ± warfarin 
CONKO-011: Rivaroxaban in the treatment of 
VTE in cancer patients 
NCT02583191 Rivaroxaban Enoxaparin /Tinzaparin 
/ Dalteparin 
COSIMO: A non-interventional study on Xarelto 
for treatment of VTE and prevention of recurrent 
VTE in patients with active cancer 
NCT02742623 Rivaroxaban Following 4 weeks 
therapy with LMWH and/or warfarin 
 
Observational 
Hong Kong study: A prospective study of 
dabigatran etexilate as primary treatment of 
malignancy-associated venous thromboembolism  
NCT03240120 Tinzaparin 175 IU/kg daily for 6 
days, then dabigatran 150 mg bid 
from day 6 onward till 6 months after 
underlying disease remission  
Observational 
 
Bleeding is of GI origin mostly and is associated with 
neoplasms of the GI system. Based on the available 
evidence, DOACs could constitute a reliable choice in 
patients at low risk of bleeding, provided that no 
interactions exist between systemic and anticoagulant 
therapy, their greatest advantage being the ease of use and 
improving patient quality of life. However, only two of the 
DOAC family, namely rivaroxaban and edoxaban, have 
been tested in randomized trials and more research is 
warranted. Indeed, several trials are ongoing and the 
medical community awaits their results with great interest 
(Table 2). 38 Scientific societies have started to update 
obsolete guidelines and recommendations to include use of 
DOACs, and more statements are expected soon in order 
to establish DOAC’s position in the therapeutics of cancer 
patients.  
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